News | August 14, 2014

First U.S. Commercial Neuraceq Scan for Beta-amyloid Plaque Imaging Performed at WVU Healthcare

First U.S. Commercial Neuraceq Scan Beta-amyloid Plaque Imaging  WVU Healthcare

August 14, 2014 ? Piramal Imaging announced that WVU Healthcare in West Virginia, is the first center in the United States to perform commercial scans using Neuraceq. Neuraceq became available for commercial use on Aug. 1, marking the first time patients are able to receive Neuraceq scans in the United States outside of research studies.

Neuraceq, which received marketing authorization in the European Union and in the United States earlier this year, is a radiopharmaceutical indicated for positron emission tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. A negative beta-amyloid scan may help rule out AD as a cause of a patient’s cognitive decline. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Prior to the availability of this technology a confirmation of the clinical diagnosis of AD could only be accomplished through autopsy.

The U.S. Food and Drug Administration (FDA) approved Neuraceq earlier this year.  Neuraceq scans will be available commercially for referring physicians and patients across the United States in the coming weeks and months.

”At WVU Healthcare, we are making history as the first center in the U.S. to offer patients access to beta-amyloid imaging with florbetaben without enrolling in a research trial,” said Gary D. Marano, medical director of nuclear medicine and PET/CT. “For us as clinicians, it’s a new diagnostic option to offer patients and referring physicians in cases of cognitive decline and concerns for Alzheimer’s disease.”

“As a company dedicated to innovation in molecular imaging, it was important to deliver Neuraceq into hands of trained dementia experts as soon as possible to start advancing treatment options and improving patient outcomes.” said Friedrich Gause, COO, Piramal Imaging. “We view this as an important milestone but just the beginning of our work to bring beta-amyloid imaging to the U.S. patient population.”

For more information: www.piramal.com/imaging

Related Content

MaxQ AI Receives FDA Clearance for Accipio Ix Intracranial Hemorrhage Platform
Technology | Artificial Intelligence | November 07, 2018
MaxQ AI announced that its Accipio Ix intracranial hemorrhage (ICH) detection software has received 510(k) clearance...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
Fans of Opposing Soccer Teams Perceive Games Differently

Image courtesy of University of York

News | Neuro Imaging | October 25, 2018
Scientists have scanned the brains of die-hard soccer fans to find out why supporters of rival teams often have very...
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...
Technology and Radionucleotide Development Will Fuel Mobile Gamma Camera Adoption
News | Nuclear Imaging | September 27, 2018
Advancements in healthcare technology, particularly in the surgery category, have led to an increasing adoption of...
Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...